Geoffrey F. Joyce

Jul 22, 2024 | healthpolicy.usc.edu | Karen Van Nuys |Stephanie Hedt |Geoffrey F. Joyce |Darius Lakdawalla

Patients and consumers bear the costs of an inefficient pharmaceutical distribution system through higher costs at the pharmacy counter and reduced access to critical therapies. As policymakers consider reforms to the drug supply chain, they should keep five principles in mind to ensure better outcomes for patients.

Aug 4, 2023 | elsoldemexico.com.mx | Geoffrey F. Joyce

Producir medicamentos de bajo costo no es tan atractivo para los laboratorios como dedicarse a elaborar ciertos productos que son nuevos, y por lo tanto más costososGeoffrey JoyceLa ira pública por los altos precios de los medicamentos ha pasado recientemente a un segundo plano ante un problema más insidioso: no hay medicamentos, a ningún precio.

Aug 4, 2023 | pbn.com | Geoffrey F. Joyce

Past public ire over high drug prices has recently taken a back seat to a more insidious problem – no drugs at any price. Patients and their providers increasingly face limited or nonexistent supplies of drugs, many of which treat essential conditions. The American Society of Health System Pharmacists now lists over 300 active shortages,… You must be a paid subscriber to read this content. To keep reading and receive unlimited access subscribe today for only $1. Subscribe NowAlready a Subscriber?

Jul 28, 2023 | bluelight.org | Geoffrey F. Joyce

Why Cheap Generic Drugs Are Harder to Find​Pain News NetworkBy Dr. Geoffrey Joyce27 July 2023Excerpts:(TLDR?)Summary:The U.S. is grappling with a growing issue of drug shortages, especially concerning essential generics. Over 300 drugs are currently in short supply, many being vital, decades-old generics.

Jul 25, 2023 | popularresistance.org | Geoffrey F. Joyce

Above Photo: There is presently no end in sight to the drug supply shortage. FG Trade/E+ via Getty Images. Blame Capitalism? The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs. Past public ire over high drug prices has recently taken a back seat to a more insidious problem – no drugs at any price.